Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. carries a market capitalization of 9.55B, placing it among publicly traded companies globally. Its enterprise value stands at 12.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.55B |
| Enterprise Value | 12.63B |
Share Statistics
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. currently has 314.82M shares outstanding.
| Shares Outstanding | 314.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 23.31. The price-to-sales ratio is 6.17, and the price-to-book ratio stands at 9.73.
| PE Ratio | 23.31 |
| PS Ratio | 6.17 |
| PB Ratio | 9.73 |
| P/TBV Ratio | 4.62 |
| P/FCF Ratio | 8.00 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 20.32 and an EV/FCF ratio of 8.46. The EV/Sales ratio of 6.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.32 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.86 |
| EV / EBITDA | 20.32 |
| EV / EBIT | 20.32 |
| EV / FCF | 8.46 |
Financial Position
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 67.99, indicating elevated leverage, while an interest coverage ratio of 13.00 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.14 |
| Quick Ratio | 0.40 |
| Debt / Equity | 67.99 |
| Debt / EBITDA | 3.25 |
| Interest Coverage | 13.00 |
Financial Efficiency
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. posts a return on equity of 49.00 and a return on invested capital of 13.10.
| Return on Equity (ROE) | 49.00 |
| Return on Assets (ROA) | 9.83 |
| Return on Invested Capital (ROIC) | 13.10 |
| Return on Capital Employed (ROCE) | 21.04 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.99 |
Taxes
Over the trailing twelve months, Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. has paid 50.89M in income taxes, reflecting an effective tax rate of 9.76.
| Income Tax | 50.89M |
| Effective Tax Rate | 9.76 |
Stock Price Statistics
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s stock has declined approximately -20.12163% over the past 52 weeks. The 50-day moving average sits at 29.30, while the 200-day moving average is 34.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -20.12163% |
| 50-Day Moving Average | 29.30 |
| 200-Day Moving Average | 34.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. generated 1.84B in revenue and converted that into 487.28M in net income, yielding earnings per share of 1.51. EBITDA reached 621.64M, while operating income came in at 621.64M.
| Revenue | 1.84B |
| Gross Profit | 1.27B |
| Operating Income | 621.64M |
| Pretax Income | 521.31M |
| Net Income | 487.28M |
| EBITDA | 621.64M |
| EBIT | 621.64M |
| Earnings Per Share (EPS) | 1.51 |
Balance Sheet
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. holds 770.18M in cash and equivalents against 2.02B in total debt, resulting in a net debt position of 1.19B. Total book value stands at 1.17B, with working capital of 276.69M providing operational flexibility.
| Cash & Cash Equivalents | 770.18M |
| Total Debt | 2.02B |
| Net Debt | 1.19B |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 3.82 |
| Working Capital | 276.69M |
Cash Flow
After subtracting -1.45B in capital expenditures, free cash flow totaled -1.45B - equivalent to -4.75 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.45B |
| Free Cash Flow | -1.45B |
| FCF Per Share | -4.75 |
Margins
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. operates with a gross margin of 68.92, reflecting its pricing power and cost economics. The operating margin of 33.76 and net profit margin of 26.46 provide insight into operational efficiency.
| Gross Margin | 68.92 |
| Operating Margin | 33.76 |
| Pretax Margin | 28.31 |
| Profit Margin | 26.46 |
| EBITDA Margin | 33.76 |
Dividends & Yields
The company's payout ratio of 49.68 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.74 |
| Dividend Yield | N/A |
| Payout Ratio | 49.68 |
| Shareholder Yield | -7.75 |
| FCF Yield | 12.50 |
Scores
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. posts an Altman Z-Score of 3.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.34 |